News

Yupelri (revefenacin) is not superior to Spiriva (tiotropium) at improving lung function in adults with severe chronic obstructive pulmonary disease (COPD), according to data from a Phase 4 clinical trial. The head-to-head study, called PIFR-2 (NCT05165485) and sponsored by Yupelri’s co-developers Theravance Biopharma and…

Two international Phase 3 clinical trials testing the investigational antibody itepekimab in people with chronic obstructive pulmonary disease (COPD) are continuing to enroll patients — specifically, former smokers — at hundreds of centers worldwide, with several new sites recently opened in the U.S. All of the new sites are…

The number of people worldwide with chronic obstructive pulmonary disease (COPD) is predicted to increase by 23% in three decades, amounting to nearly 600 million patients by 2050, according to a new study. The largest increase, by nearly 50%, is projected to be among women and people living in…

Treatment with Dupixent (dupilumab) — approved in the U.S. for five inflammatory conditions, to date — once again resulted in significantly fewer exacerbations, or periods of sudden symptom worsening, among people with moderate to severe chronic obstructive pulmonary disease (COPD) in the second of two similarly designed Phase 3…

Long-term treatment with Olympus’ Spiration Valve System (SVS) safely led to sustained improvements in lung function — and in life quality — among people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). That’s according to two-year follow-up data from the EMPROVE trial, which had tested…

Treatment with the anti-inflammatory medication eblasakimab opened the airways of lung samples from people with chronic obstructive pulmonary disorder (COPD) in laboratory experiments. The findings were shared by Aslan Pharmaceuticals, the company that’s developing eblasakimab, in an oral presentation at the Dermatology Drug Development Summit, held recently in…

The American Lung Association has launched an initiative that has as its goal improving the quality of life of people who’ve been living with chronic obstructive pulmonary disease (COPD) for at least a decade. The “COPD for…

The U.S. Food and Drug Administration (FDA) has approved ReAlta Life Sciences’ request to launch a Phase 2 clinical trial testing its experimental anti-inflammatory therapy RLS-0071 in people with chronic obstructive pulmonary disease (COPD) who are experiencing disease exacerbations. Exacerbations, or disease flare-ups, may occur several times per year…

From a Lace Up for Lungs challenge to learning about the impact of chronic obstructive pulmonary disease (COPD) in individual U.S. states, supporters are poised to participate in COPD Awareness Month, observed each November. World COPD Awareness Day is Nov. 15. Each fall, the COPD Foundation and the…

Ensifentrine, an investigational medication under review in the U.S. for chronic obstructive pulmonary disease (COPD), is effective across key patient subgroups, including when patients are separated by their history of lung exacerbations and type of background therapy. That’s according to recent pooled analyses from the ENHANCE-1 (NCT04535986) and…